Breaking News, Financial News

Financial Report: Roche

Pharmaceutical sales up 4% YTD

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche   YTD Revenues: 34.9 billion CHF (+3%)   Comments: Pharmaceutical sales were 27.2 billion CHF, up 4% driven by cancer drugs Avastin, Herceptin, MabThera/Rituxan, Perjeta and Kadcyla, as well as rheumatoid arthritis treatment Actemra/RoActemra. The HER2 breast-cancer franchise, which includes Herceptin, Perjeta and Kadcyla, grew 13%. Avastin sales rose 13% due to recent approvals in ovarian cancer in Europe, colorectal cancer in the U.S. and Europe, and the first approval for newly diagnose...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters